|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 2 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 3 | Safety,activity, and immune con'elates of Anti-PD-I antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 4 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer 显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 5 | Safety,activity,and immunecorrelates of anti-PD-1 antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | Engl J Med2012，366，26： | 1 |
| 6 | Targeting the PD-1/B7- HI(PD-L1) pathway to activate anti-tumor immunity 显示文摘 | Topalian SL Drake CG Pardoll DM | 2012 | Cur- rent opinion in immunology2012，24，2： | 1 |
| 7 | Phase I trial of subcutaneous interlukin-6 in patientswith advanced malignancies显示文摘 | Weber J Yang JC Topalian SL | 1993 | J Clin Oncol1993，11，： | 1 |
| 8 | Immunothera- py of patients with advanced cancer using tumor-infil- trating lymphocytes and recombinant interleukin-2: a pi- lot study显示文摘 | Topalian SL Solomon D Avis FP | 1988 | J Clin Oncol1988，6，5： | 1 |
| 9 | Safety, activity, and immune correlates of Anti-PD-1 antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 10 | Safety, activity, and correlates of anti-PD-1 antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 11 | Targeting the PD-1/B7-II1 ( PD-L1 ) pathway to activate anti-tumor immunity显示文摘 | Topalian SL Drake CG Pardoll DM | 2012 | Curt Opin Immunol2012，24，2： | 1 |
| 12 | Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity 显示文摘 | Topalian SL Drake CG Pardoll DM | 2012 | Curr Opin Immunol2012，24，2： | 1 |
| 13 | Safety, activity, and immune correlates of anti-PO-l antibody in cancer显示文摘 | Topalian SL Hodi FS BrahmerJR | 2012 | N EnglJ Med2012，366，26： | 1 |
| 14 | Targeting the PD-1/ BT-H1 ( PILL1 ) pathway to activate anti-tumor immunity 显示文摘 | Topalian SL Drake CG Pardoll DM | 2012 | Curr Opin Immunol2012，24，2： | 1 |
| 15 | Safety,activity,and immune correlates of anti-PD-1 antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 16 | Safety,activity,and immune correlates of anti-PD-1 antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 17 | Safety,activity,and immune correlates of anti-PD-1 antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 18 | Cancer immunotherapy comes of age显示文摘 | Topalian SL Weiner G J Pardoll DM | 2011 | J Clin Oncol2011，29，36： | 1 |
| 19 | Tumor-specific cytolysis by lymphocytes infiltrating human melanomas显示文摘 | Topalian SL Solomon D Rosenberg SA | 1989 | J Immunol1989，142，10： | 1 |
| 20 | Safety, activity, andimmune correlates of anti-PD-1 antibody in cancer 显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl JMed2012，366，26： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员